Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts

by @JTC_PALIdev | May 24, 2023 | Press Releases

Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose optimization study with 25% enrollment complete Carlsbad, CA, May 24, 2023 — Palisade Bio, Inc. (Nasdaq: PALI)...

Palisade Bio Reports First Quarter 2023 Financial Results

by @JTC_PALIdev | May 12, 2023 | Press Releases

Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic...

Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

by @JTC_PALIdev | May 11, 2023 | Press Releases

Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be completed in Q3 2023 Carlsbad, CA, May 11, 2023 — Palisade Bio, Inc....

Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148

by @JTC_PALIdev | Apr 6, 2023 | Press Releases

Carlsbad, CA, April 06, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the Canadian Intellectual Property...

Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148

by @JTC_PALIdev | Apr 5, 2023 | Press Releases

Enrollment triggers milestone payment Carlsbad, CA and Shanghai, China, April 05, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic...

Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

by @JTC_PALIdev | Apr 3, 2023 | Press Releases

Carlsbad, CA, April 03, 2023 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional...